Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China · Delayed Price · Currency is CNY 19.06
+0.36 (1.93%)
Jun 10, 2026, 4:00 PM EDT
SHE:301263 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 678.87 | 674.02 | 720.17 | 760.07 | 782.8 | 653.65 |
Other Revenue | 0.88 | 0.88 | 0.86 | 0.72 | 0.68 | - |
| 679.75 | 674.9 | 721.03 | 760.79 | 783.48 | 653.65 | |
Revenue Growth (YoY) | -5.14% | -6.40% | -5.23% | -2.90% | 19.86% | -7.80% |
Cost of Revenue | 317.12 | 317.6 | 319.09 | 303.93 | 328.67 | 326.37 |
Gross Profit | 362.62 | 357.3 | 401.94 | 456.85 | 454.81 | 327.28 |
Selling, General & Admin | 284.25 | 269.3 | 203.97 | 202.59 | 211.83 | 163.4 |
Research & Development | 76.36 | 77.68 | 86.42 | 62.89 | 40.39 | 26.46 |
Other Operating Expenses | 3.15 | 2.42 | 1.73 | 3.78 | 4.35 | 7.08 |
Operating Expenses | 363.96 | 351.46 | 291.88 | 273.14 | 260.03 | 199.77 |
Operating Income | -1.33 | 5.84 | 110.06 | 183.71 | 194.78 | 127.5 |
Interest Expense | -13.92 | -12.63 | -8.63 | -1.7 | -2.58 | -4.72 |
Interest & Investment Income | 4.91 | 3.94 | 9.51 | 16.48 | 19.13 | 0.87 |
Currency Exchange Gain (Loss) | -0.57 | -0.57 | -2.3 | -0.88 | -4.34 | 0.53 |
Other Non Operating Income (Expenses) | 0.82 | -0.34 | -0.16 | -0.12 | -0.11 | -0.25 |
EBT Excluding Unusual Items | -10.1 | -3.76 | 108.48 | 197.49 | 206.88 | 123.93 |
Gain (Loss) on Sale of Investments | -0.19 | 0.2 | 0.1 | 0.8 | 0.65 | - |
Gain (Loss) on Sale of Assets | 0.13 | 0.19 | - | 0.15 | 0.01 | -0.02 |
Asset Writedown | -1.39 | -0.9 | -1.27 | -7.61 | -0.3 | -0.5 |
Other Unusual Items | -3.9 | -3.9 | -1.74 | 1.5 | 0.12 | 14.14 |
Pretax Income | -15.46 | -8.17 | 105.57 | 192.32 | 207.35 | 137.54 |
Income Tax Expense | -22.42 | -20.92 | 8.53 | 38.82 | 32.75 | 17.55 |
Earnings From Continuing Operations | 6.97 | 12.75 | 97.04 | 153.5 | 174.6 | 120 |
Minority Interest in Earnings | 18.7 | 15.89 | 11.18 | 6.7 | 0.01 | 0.07 |
Net Income | 25.67 | 28.63 | 108.22 | 160.2 | 174.61 | 120.07 |
Net Income to Common | 25.67 | 28.63 | 108.22 | 160.2 | 174.61 | 120.07 |
Net Income Growth | -72.78% | -73.54% | -32.45% | -8.25% | 45.43% | -25.34% |
Shares Outstanding (Basic) | 478 | 491 | 499 | 506 | 476 | 381 |
Shares Outstanding (Diluted) | 478 | 491 | 499 | 506 | 476 | 381 |
Shares Change (YoY) | -6.32% | -1.66% | -1.27% | 6.23% | 24.85% | 6.51% |
EPS (Basic) | 0.05 | 0.06 | 0.22 | 0.32 | 0.37 | 0.31 |
EPS (Diluted) | 0.05 | 0.06 | 0.22 | 0.32 | 0.37 | 0.31 |
EPS Growth | -70.94% | -73.10% | -31.58% | -13.63% | 16.49% | -29.90% |
Free Cash Flow | -89.83 | -121.16 | 20.78 | -106.48 | 58.94 | 75.38 |
Free Cash Flow Per Share | -0.19 | -0.25 | 0.04 | -0.21 | 0.12 | 0.20 |
Dividend Per Share | 0.042 | 0.042 | 0.167 | 0.250 | 0.324 | 0.162 |
Dividend Growth | -74.98% | -74.98% | -33.32% | -22.86% | 100.06% | - |
Gross Margin | 53.35% | 52.94% | 55.74% | 60.05% | 58.05% | 50.07% |
Operating Margin | -0.20% | 0.86% | 15.26% | 24.15% | 24.86% | 19.51% |
Profit Margin | 3.78% | 4.24% | 15.01% | 21.06% | 22.29% | 18.37% |
Free Cash Flow Margin | -13.22% | -17.95% | 2.88% | -14.00% | 7.52% | 11.53% |
EBITDA | 65.15 | 69.59 | 162.89 | 221.01 | 226.75 | 155.09 |
EBITDA Margin | 9.59% | 10.31% | 22.59% | 29.05% | 28.94% | 23.73% |
D&A For EBITDA | 66.48 | 63.75 | 52.83 | 37.3 | 31.97 | 27.58 |
EBIT | -1.33 | 5.84 | 110.06 | 183.71 | 194.78 | 127.5 |
EBIT Margin | -0.20% | 0.86% | 15.26% | 24.15% | 24.86% | 19.51% |
Effective Tax Rate | - | - | 8.08% | 20.19% | 15.79% | 12.76% |
Revenue as Reported | 679.75 | 674.9 | 721.03 | 760.79 | 783.48 | 653.65 |
Advertising Expenses | - | 109.38 | 65.86 | 71.69 | 95.69 | 61.51 |